Programme
| Sunday 3 November 2024 | ||||
|---|---|---|---|---|
Time |
Track #1 |
Track #2 |
Track #3 |
Track #4 |
13:00 – 15:00 |
IS1 |
IS2 |
IS3 |
IS4 |
"From bench to bedside" |
ISAC / ICC Early Career Scientist Workshop |
Building an Antimicrobial Stewardship Programme Challenges and Achievements |
Sustainability and IPC |
|
Basics of antibiotic pharmacokinetics / pharmacodynamics Use of in vitro and in vivo models to elucidate the PK/PD driver of antimicrobial activity Optimising antibiotic treatment in patients using PK/PD |
Building the ASP in a Turkish Referral Hospital Insights from a resource rich setting Perspectives from South America |
Do we really need those gloves? Gowns and respiratory viruses Scrub, scrub, scrub… which surfaces and why should be disinfected |
||
15:00 – 15:30 |
Coffee |
|||
15:30 – 17:30 |
IS5 |
IS6 |
IS7 |
IS8 |
"From bench to bedside" |
Getting Your Paper Published: What You Need to Know as an Author |
Improving Antimicrobial Use in Intensive Care Units |
One Health Workshop |
|
Standardization of antimicrobial susceptibility testing – Where are we? Obstacles and challenges in implementation of EUCAST methodology (and how to overcome them) What to do when there are no breakpoints in the EUCAST table? |
Overview of the latest developments in the publishing industry / How to get published What Editors Look For: Insights from the Journal of Global Antimicrobial Resistance Editor-in-Chief What Editors Look For: Insights from an Editor of the International Journal of Antimicrobial Agents |
Is broad spectrum antibiotics always necessary for patients admitted with sepsis to ICU? Antibiotic de-escalation in ICU: is it worth it? Bioanalytical innovations to guide evidence-based antimicrobial dosing in the ICU |
||
17:30 – 18:30 |
Opening Reception and Award Ceremony |
|||
18:30- 19:30 |
Plenary Lecture 1 | |||
ISAC’s Hamao Umezawa Memorial Award (HUMA) |
||||
Monday 4 November 2024 |
|||
|---|---|---|---|
Time |
Track #1 |
Track #2 |
Track #3 |
09:00 – 10:00 |
Plenary Lecture 2 |
||
mRNA Vaccine Platform Today and Tomorrow |
|||
10:00 – 10:30 |
Coffee and Exhibition |
||
10:30 – 12:00 |
SY 1 |
SY 2 |
SY 3 |
Artificial Intelligence in Anti-infectives |
Bacteriophage therapy: Where are we now? |
Changing paradigms and new approaches in clinical microbiological diagnosis |
|
Tracking antibiotic resistance with artificial intelligence Optimising antibiotic use with model-informed precision dosing Treating infectious diseases with machine-learning based prediction models |
Phage pharmacokinetics: Why does it matter? Phage therapy: How to build a bridge between researchers and clinicians? Personalised phage therapy: Where are we now? |
Biomarkers, emergency admission and triaging: recognising the ill looking well and the well looking ill Syndromic Diagnostic Tests: New approach in microbiological diagnosis Impact of NGS-assisted diagnostics on the diagnosis of infectious diseases |
|
12:00 – 13:30 |
Industry Symposium |
||
13:30 – 15:00 |
SY 4 |
SY 5 |
SY 6 |
HIV prevention, inflammation and metabolic disorders |
Emerging and Reemerging Infections among Migrants |
Antimicrobial stewardship in critical care units |
|
HIV prevention current situation and beyond Lipid disorders in people living with HIV Is there a chance to control chronic inflammation |
AMR in migrants and conflicts, a perfect storm Group A streptococci, Diphtheriae and other bacterial vaccine-preventable infections in refugees Outbreaks in conflicts: the case of leishmania |
Are broad spectrum antibiotics always necessary for patients admitted with sepsis to the ICU? Antibiotic de-escalation in the ICU : is it worth it ? Bioanalytical innovations to guide evidence-based antimicrobial dosing in the ICU |
|
15:00 – 16:00 |
Coffee / Poster Session 1 |
||
16:00 – 17:00 |
Plenary Lecture 3 |
||
Infectious diseases and wars: past and present |
|||
17:00-17:30 |
KN 1 |
KN 2 |
|
Averting the antimicrobial resistance crisis: barriers to effective antimicrobial stewardship |
Antimicrobial Collateral Risk on Microbiota |
||
19:00 – 21:30 |
Industry Symposium / Dinner |
||
Tuesday 5 November 2024 |
|||
|---|---|---|---|
Time |
Track #1 |
Track #2 |
Track #3 |
09:30-10:00 |
KN 3 |
KN 4 |
|
Antimicrobial resistance and immunocompromised patients: Past – Today – Tomorrow |
Infection Control |
|
|
10:00 – 10:30 |
Coffee and Exhibition |
||
10:30 – 12:00 |
SY 7 |
SY 8 |
SY 9 |
Diagnostic and Treatment Strategies for Infections Caused by High-Risk Gram negative bacteria |
The pandemic “goes away”, the real pandemic is here: Sepsis 2024 |
WHO Fungal priority pathogen list- Challenges in the diagnosis and management |
|
Resistance and virulence features of hypermucoviscous Klebsiella pneumoniae from bloodstream infections Clinical Impact and Public Health Implications of High-Risk E. coli Clones Molecular Epidemiology and Global Spread of Hypervirulent Acinetobacter spp. and Pseudomonas spp. |
Immune classification: the time has come Laboratory diagnosis (Biomarkers & molecular diagnostics) in sepsis – do they really help? Holistic patient management: does this exist? |
Azole resistant Aspergillus fumigatus in clinics and environment: from screening to containment policy Treatment of Cryptococcal infections – where are we heading? Emergence of spread of resistance in Candida species |
|
12:00 – 13:30 |
Industry Symposium |
||
13:30 – 15:00 |
SY 10 |
SY 11 |
SY 12 |
Impact of the WHO National AMR action plans: Success stories |
How vaccines are changing the AMR landscape |
Osteoarticular infections |
|
Success stories from Middle East Success stories from Latin America Success stories from Asia |
Antimicrobial resistance in the 21st century How vaccines have changed the AMR landscape so far in the 21st century Potential for further impacts on AMR from current and future vaccines |
A multicentre evaluation and expert recommendations of use of the newly developed BioFire Joint Infection polymerase chain reaction panel Mycobacterial Prosthetic Joint infections Novel and Long acting anti gram positive antibiotics implication for bone and joint infections |
|
15:00 – 16:00 |
Coffee / Poster Session 2 |
||
16:00 – 17:00 |
Plenary Lecture 4 |
||
Diagnostic – Molecular Diagnostic |
|||
| Wednesday 6 November 2024 | |||
|---|---|---|---|
Time |
Track #1 |
Track #2 |
Track #3 |
08:30 – 09:00 |
KN 5 |
KN 6 |
|
Pandemic Preparedness and Lessons Learnt |
Emerging Antifungal Resistance |
||
09:00 – 10:00 |
Plenary Lecture 5 |
||
Antimicrobial resistance in the 21st century |
|||
10:00 – 10:30 |
Coffee and Exhibition |
||
10:30 – 12:00 |
SY 13 |
SY 14 |
SY 15 |
The built environment of the hospital and nosocomial infections; sources and transmission routes |
Antimicrobial resistance and one health |
Advances in the diagnosis and treatment of tuberculosis and new risks for public health. |
|
Acinetobacter species all around the ward; risks, causes and prevention Hospital design matters! The built environment of the hospital and infection prevention; lessons of the past pandemic, prepared for the future? |
Antimicrobial resistance in animals Transmission risk of multidrug-resistant organisms from household animals Clinical significance of probiotics in controling antimicrobial resistance |
Conventional and molecular diagnosis methods for rapid and accurate detection of TB: Old but gold? Update on diagnosis and treatment of M. abscessus infections Multidrug resistant tuberculosis in migrants, a global threat |
|
12:00 – 13:30 |
Industry Symposium |
||
13:30 – 15:00 |
SY 16 |
SY 17 |
SY 18 |
Evidence based approach to AMR in hospitals |
New Frontiers in so-called Untreatable Viral Infections |
Hot Topics in Hepatitis |
|
Evidence based infection control of MDR gram negative bacteria Antimicrobial stewardship: clinical trial, modelling and qualitative studies Evidence base from randomised controlled trials in treatment of bacteraemia to combat AMR |
Mechanisms of Latent Virus Activation in Immunocompromised Populations Advances in Treatment of Polyoma Virus Disease Antibodies against the infectious agents: Current challenges and opportunities |
Retreatment of Chronic Hepatitis C patients failing first line regimens Hepatitis B virus vaccine; What is new? Emerging and re-emerging viruses and hepatic compromise |
|